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Abstract 
Traumatic brain injury is common and yet effective treatments of the secondary brain 
injury are scarce. Melatonin is a potent, non-selective neuroprotective and anti-
inflammatory agent that is showing promising results in neonatal brain injury. The aim of 
this study was to systematically evaluate the pre-clinical and clinical literature for the 
effectiveness of Melatonin to improve outcome after TBI. Using the systematic review 
protocol for animal intervention studies (SYRCLE) and Cochrane methodology for clinical 
studies, a search of English articles was performed. Eligible studies were identified and 
data was extracted. Quality assessment was performed using the SYRCLE risk of bias tool. 
Meta-analyses were performed using standardized mean differences (SMD). Seventeen 
studies (15 pre-clinical, 2 clinical) met inclusion criteria. There was heterogeneity in the 
studies, and all had moderate-to-low risk of bias. Meta-analysis of pre-clinical data 
revealed an overall positive effect on neurobehavioural outcome with SMD of 1.51 (95% 
CIs: 1.06-1.96). Melatonin treatment had a favorable effect on the neurological status, by a 
SMD of 1.35 (95% CI: 0.83-1.88) and cognition by a SMD of 1.16 (95% CIs: 0.4-1.92). 
Melatonin decreased the size of the contusion by a SMD of 2.22 (95% CI: 0.84-3.59) and 
cerebral oedema by SMD of 1.91 (95% CI: 1.08-2.74).  Only two clinical studies were 
identified. They were of low quality,  used for symptom management, and were of 
uncertain significance. In conclusion, there is evidence that Melatonin treatment after TBI 
significantly improves both behavioural outcomes and pathological outcomes, but 
significant research gaps exist especially in clinical populations. 
 
Key Words: Traumatic Brain Injury, Melatonin, Systematic Review 
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Introduction 
Traumatic brain injury is one of the commonest causes of neurological morbidity and 
death worldwide 1. Recent estimations suggests an incidence of 790/100,000 person years 
2. Despite being common, evidence supporting its management and specific treatments 
are lacking 3. After the acute injury, a torrent of complex and varied pathophysiological 
processes ensue that unfortunately result in further significant secondary brain injury but 
that also potentially offers a therapeutic window 4. Part of the problem in making 
treatment advances is that the injuries themselves are diverse, and they occur in markedly 
varied biopsychosocial settings, which influences outcome. As many treatments that have 
focused on a specific pathway or symptom have failed to show efficacy in human studies, 
it becomes attractive to consider a non-selective agent as a therapeutic candidate 5, 6.  
Melatonin (MEL) could be a promising neuroprotective agent in traumatic brain injury 
(TBI). Although MEL’s role in the chrono-regulation of major physiological processes (e.g., 
the sleep wake cycle) is well accepted 7, 8, more recently its therapeutic potential is being 
explored in acquired brain injury, most notably neonatal hypoxic-ischemic encephalopathy 
9-11.  MEL  has pluripotent antioxidant and anti-inflammatory properties 12-15, that  are both 
receptor-mediated (at physiological levels) and non-receptor mediated (especially at 
supra-physiological levels) 16-19. Further its lipophilic properties allow it to cross cell 
membranes easily and reach subcellular compartments 20. The latter is a useful property 
considering that TBI results in widespread cellular process disruption such as metabolic 
cascades, indiscriminant neurotransmitter release, oxidative stress, and mitochondrial 
dysfunction. Indeed a recent Neurotrauma Pharmacology working group identified a need 
for pharmacotherapies that promote neurorepair, neuroregeneration, and 
neuroprotection 6. 
Melatonin affords neuroprotection through a wide variety of mechanisms 18 including;  
acting as a direct free radical scavenger and anti-oxidant21 through reduction in oxidative 
stress by decreasing oxidative/nitrosative species and by increasing antioxidant enzymes22-
25. MEL also improves mitochondrial function by increasing electron transport and the 
function of complexes I and IV and by decreasing direct mitochondrial oxidative damage 26-
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 O
f Q
ue
en
sla
nd
 fr
om
 w
ww
.lie
be
rtp
ub
.co
m 
at 
07
/15
/18
. F
or 
pe
rso
na
l u
se 
on
ly.
 
Page 6 of 50 
 
 
 
6 
Jo
ur
na
l o
f N
eu
ro
tr
au
m
a 
M
el
at
on
in
 a
s a
 tr
ea
tm
en
t a
fte
r T
ra
um
at
ic 
Br
ai
n 
In
ju
ry
: A
 sy
st
em
at
ic 
re
vi
ew
 a
nd
 m
et
a-
an
al
ys
is 
of
 th
e 
pr
e-
cli
ni
ca
l a
nd
 cl
in
ica
l l
ite
ra
tu
re
&
#1
3;
  (
DO
I: 
10
.1
08
9/
ne
u.
20
18
.5
75
2)
 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
28. As an indirect and direct consequence of these actions, MEL has also been shown to 
inhibit programmed cell death (apoptosis), is also inhibited by MEL 29-31. 
In addition to protection from toxic metabolic intermediaries, MEL has also been shown to 
modulate neurotransmitter effects in TBI and other neurological conditions. Excessive 
release of the excitatory neurotransmitter glutamate occurs immediately after TBI 32. MEL 
has the potential to “balance” this due to its action at inhibitory gamma-aminobutyric acid 
(GABA) receptors, especially GABAA receptors 33-36. It has been also shown to decrease the 
neurotoxicity associated with beta-amyloid which accumulates in several 
neurodegenerative diseases including chronic traumatic encephalopathy (CTE) 37. 
Neuroinflammation is also thought to play a role in TBI and CTE 38. Although inflammation 
and glial cell activation after TBI can be beneficial, if excessive it can lead to significant 
damage and impaired function. Melatonin. MEL is a potent anti-inflammatory agent 13, 39, 
40. It achieves this partly through cytokine signaling and also indirectly by decreasing the 
inflammatory mediators nitric oxide and maldondialdehye production 41.  
Not only is MEL attractive due to its neuroprotective properties, but it also offers 
therapeutic potential for many of the common post-TBI symptoms such as sleep 
disruption, pain, mood disturbance and increased anxiety 42-47. Melatonin can help the 
initiation of sleep via its action on Melatonin receptors48 and can also decrease pain both 
at the tissue level and by modulating the opioid and GABAergic systems 49, 50. Melatonin  
may be useful in migraine 51, 52 and has efficacy in disorders of chronic pain and anxiety 53, 
54. Importantly, Melatonin has an excellent side effect profile with good tolerability in high 
does and even in children 55-57.  
In summary, Melatonin may offer safe non-selective neuroprotection and symptomatic 
treatment following TBI. The aim of this study was determine the effect of treatment with 
Melatonin (or other melatonergic agent) on the outcome (anatomical, cognitive, physical, 
or behavioural) after TBI compared to control or usual care in either humans or animals. 
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Methods: 
The following databases were comprehensively searched between July and December 
2017 by investigator KMB: The Cochrane Central Register of Controlled Trials (CENTRAL, 
The Cochrane Library), PubMed (1951- December 2017), CINAHL (1982- December 2017), 
PsycINFO (1966- December 2017), MEDLINE (OVID) (1948 to Dec 2017), Embase (1988- 
December 2017) and the National Institute of Health Clinical Trials Database, 2017. The 
following search strategy was used using the MeSH headings or Keywords: 1) Human 
OR Animal AND Brain injuries AND Melatonin OR N-acetyl-5-methoxytryptamine OR 
melatonergic agent AND child development OR infant development OR cognition OR 
intellectual disability OR developmental disabilities OR psychomotor performance OR 
psychomotor disorders OR sleep OR psychological OR behaviour OR language OR outcome 
OR mortality OR morbidity OR brain damage, chronic. Studies were included if they were 
reported in English or if translations could be obtained from the author. 
 
Selection criteria: 
Studies had to meet the following selection criteria for inclusion: (1) randomized 
controlled trial (RCT) or comparative trials using a control group or case series (greater 
than 10 participants) satisfying inclusion criteria for types of participants, interventions 
and outcomes. (2) The study population included adults and children (ages 0 to 19 years, 
including neonates) and animals with a traumatic brain injury. (3) Treatment with 
Melatonin OR N-acetyl-5-methoxytryptamine OR melatonin analog or melatonergic agent. 
The intervention group had to have been compared to a group receiving sham, placebo or 
other non-experimental control in the animal. In the human, in order to be inclusive, the 
same criteria as for the animal were used and also included case series. (4) Treatment 
could begin either before the injury or at any time point post injury and could be provided 
in the lab, at home, or in hospital. (5) Any validated outcome measure assessing 
anatomical, physical, cognitive and/or behavioural outcome.  A wide variety of measures 
tend to be employed across studies and so we did not require that each one has been 
validated in the TBI population as this was anticipated to limit the number of studies that 
could be included. Functional outcome assessed by objective, validated, reliable scales 
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were included. Studies using global outcome scores such as the Glasgow Outcome Score 
(GOS), mortality and morbidity rates were also included; and (7) full text available within a 
peer-reviewed journal, published in English. Articles that reported on the same sample 
were treated as a single study.  
Two of the authors independently (KMB, MV) assessed the eligibility of studies for 
inclusion in the review by firstly reviewing articles by title and abstract to exclude those 
not meeting inclusion criteria. Articles that appeared to meet the inclusion criteria were 
further evaluated by the full text. Consensus for article inclusion was reached by discussion 
between the authors (KMB, MV, ME).  
 
Data Extraction  
Details about the study design and population demographics were extracted from the 
included studies (Table 1). The theoretical structure, content and dosage of the 
intervention programs were tabulated (Table 2).  Relevant data from the studies were 
extracted by the first author, including outcome measures (Table 3).  
Data Synthesis  
Quantitative analysis was conducted using Review Manager (RevMan) version 5.3 software 
(The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). 
Treatment effects were first calculated separately for each study outcome. Treatment 
effects for pooled data were then calculated across trials, where possible, for specific 
outcomes and domains. For all analyses, a random effect, inverse variance model was used 
to calculate standardized mean differences (SMD) and 95% confidence intervals (CI). The 
effect of heterogeneity (I2) was used to measure the degree of inconsistency across pooled 
studies due to variability rather than chance, with larger values indicative of high 
heterogeneity.  
Data Quality 
Two independent reviewers (KMB and MV) assessed the risk of bias and the 
methodological quality using the SYstematic Review Centre for Laboratory animal 
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Experimentation (SYRCLE) Risk of Bias tool 58 for animal studies and Downs and Black 
Criteria 59 for human studies (Tables 2 and 4). The SYRCLE scale has demonstrated 
reliability and consists of 10 items each with a score of “high”, “unclear” or “low” risk of 
bias. Where no mention of treatment randomization was made then the study was 
awarded a “high” risk of bias, but randomization without mention of the process was 
given a score of “unclear”. A “low” risk of bias was awarded when baseline 
characteristics of weight, sex, age and strain of the animals were provided. When 
animals were sacrificed immediately without returning to housing then this category was 
ranked as “low” risk. If outcome was objectively assessed using computerized methods 
only then this category was awarded “low” risk of bias. Otherwise, blinding of outcome 
assessors was categorized as “high” risk when no specific mention of blinding was made. 
Selective outcome reporting was not scored as most animal protocols are not yet 
published/registered. The quality of human studies was evaluated using the Downs and 
Black quality assessment tool, which assigns an individual score calculated out of 29 total 
points for each study. Discrepancies were resolved by discussion. The protocol for this 
systematic review and meta-analysis was registered with the International Prospective 
Register of Systematic Reviews (PROSPERO; registration number PROSPERO 2017 
CRD4201707302). 
Results   
The selection process for included studies is shown in Figure 1. After removing duplicates, 
213 studies were screened by title and abstract review. Twenty-two studies were 
identified for detailed review and a further 3 studies were identified from references lists 
of review articles. Fifteen preclinical studies with unique data examining the 
neuroprotective effects of MEL and two clinical studies examining it’s use for symptom 
management after TBI were included, see Tables 1 and 2. Sample sizes were small in all 
studies, 4 to 16 in experimental preclinical groups, and 7 and 12 in clinical studies. 16 
studies were controlled trials; one study was a retrospective controlled cohort study. 
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Pre-clinical studies 
TBI Model and Severity of Injury 
A variety of animals were used: 9 rat, 5 mice and 1 rabbit, see Table 1. Most were young 
adults, although two models were juvenile rat models, postnatal day 7 and 30 70, 72. In 
keeping with the influence of sex on outcome following animal and human TBI, adult 
animals were all male, except for the rabbit model 61. Several different mechanistic models 
of TBI were employed; more focal injuries were obtained using closed head injury (CHI), 
controlled cortical impact (CCI) or fluid percussion models (FPI)30, 40, 60, 61, 64, 67-71, 74, 75, and 
diffuse injuries were obtained either by the Marmarou method 63, 65 or 
acceleration/deceleration model 72. The resultant injuries were moderate to severe in all 
cases except for one mild TBI model 72. Although Bayir et al. report their TBI model as mild 
the injuries on MRI would suggest moderate/severe TBI 61. 
Interventions:  
The range of MEL doses is shown in Table 2 and ranged from 0.625mg/kg to 200mg/kg, 
although the most frequent dose was 5mg/kg. The intervention was given once in 6 
studies60, 61, 69, 70, 74, 76 and in 9 studies the dose was repeated up to 14 times72. The total 
MEL dose was between 0.625 to 300mg/kg. The control intervention was the agent or 
vehicle used to dissolve and administer the MEL (usually ethanol and saline). All 
interventions were given by intraperitoneal injection (IP) except orally in one study 72. The 
interventions were commenced 20 minutes before the injury 69, within 5 minutes of the 
injury 30, 60, 64, 65, 67-71, 75, at 1 hour 63, 74, or 4 hours post-injury 61. No adverse events due to 
the interventions were reported in the pre-clinical studies. 
Qualitative analysis 
None of the pre-clinical studies had published protocols nor were registered with 
CAMARADES. Therefore, the selective outcome reporting item on the SYRCLE tool was not 
scored. There was insufficient information reported for many (41%) of the remaining 9 
questions which were scored as “unclear”. Overall, all studies had significant risks of bias, 
see Table 4. The average SYRCLE score was 15.3 (95% CI: 14.4, 16.1). Although 4 studies60, 
65, 68, 69 scored above the 95% CI they were not sufficiently remarkable as to be excluded 
from any analyses. Nine studies reported any randomization, although details were not 
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given. Only 30% reported any blinding, either of investigators, animal handlers or outcome 
assessors, see Figure 2. None of the studies reported sample size calculations. Indeed, nine 
studies (60%) had sample sizes of 6 per group or less.  
Outcome:  
A variety of outcome measures were used, see Table 3. The commonest were i) brain 
water content as a marker for cerebral edema (8 studies) reported between 8 and 72 
hours post injury; ii) lesion/contusion volume (7 studies) measured between 8 hours and 
14 days post-injury; iii) Neurological Symptom Scores (NSS, or variant; 5 studies) and iv) 
the Morris Water Maze test (MWM) (escape latency; used in 4 studies). The NSS when 
measured was done repeatedly between 1 hour and 7 days (see table 3). Similarly MWM 
test was measured repeatedly between day 1 and 4 post-injury except in one study68. 
These measures were used in meta-analyses of the preclinical studies. All motor outcomes 
differed in each of the 4 studies, see Table 3. Some motor outcomes required more 
balance and coordination (e.g. Rotarod test) than others (e.g. Grip test). 
Stratified meta-analyses 
There was a significant effect of treatment with MEL on both pathological outcome 
measures, Figures 2, and behavioural measures, Figures 3.  
Pathological outcomes:  Melatonin decreased the size of the contusion by a SMD of 2.22 
(95% CI: 0.84, 3.59; 6 studies, 7 comparisons). The effect size was large being greater than 
3.0 for 4 of the 6 studies with the largest being 4.540. MEL decreased cerebral oedema by 
SMD of 1.91 (95% CI: 1.08, 2.74; 6 studies, 9 comparisons).  Six of nine studies reported 
significantly large effect sizes ranging from 1.5 to 3.9. There was significant heterogeneity 
between the studies (I2: 84%). However, this finding was supported by two studies not 
included in the meta-analysis. One reported a decrease in intracranial pressure (ICP) in 
association with MEL treatment 63. In another study, MEL had a similar effect on brain 
protrusion (a marker of increased ICP) as 20% Mannitol 61 - a first-tier therapy for 
increased ICP following TBI 77.   
Behavioural outcomes: Melatonin treatment had a favorable effect on the neurological 
status, see Figure 3 by a SMD of 1.35 (95% CI: 0.83, 1.88; 5 studies 8 comparisons). The 
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outcome closest to 24 hours post-injury was compared in the meta-analysis. Five of the 8 
experiments reported significantly large effect sizes associated with MEL treatment, 
ranging from 1.0 to 3.5. Meta-analysis demonstrated that overall MEL improved the 
performance on a memory-based cognitive task by a SMD of 1.16 (95% CIs: 0.4, 1.92). 
There was a large effect size ranging from 1.1 to 2.4. Only one study examined the effect 
of MEL on mood and anxiety 72. This was done between day 7 and 13 post injury and 
showed no effect of treatment. Motor outcomes were also improved by MEL (SMD 0.93; 
95% CI:0.69, 1.93).  
Overall effect 
When all studies and comparisons were combined, the overall outcome was improved by a 
SMD of 1.51 (95% CI, 1.06, 1.96; 15 studies, 20 comparisons), see Figure 4. One outcome 
measure from each study was included in the following priority: neurological status, 
cognitive function, contusion size and cerebral oedema. As expected the heterogeneity 
was moderately high (I2 58%). Nine comparisons had effect sizes greater than 1.5. 
Dose, timing of intervention, and frequency 
Four studies examined the effect of differing doses on outcome 63, 69, 74, 75. The dose, timing 
and frequency of interventions varied greatly making it difficult to draw conclusions. The 
effects of frequency of dose regimes and timing of interventions were analyzed in ad hoc 
subgroup analyses of the overall outcome. Interventions were considered to be “early” if 
given before 30 minutes and late if given after 60 minutes, see Figure 5. There was no 
significant effect of single versus multiple dosing (Chi2 2.26, df 1; p=0.13) nor “early” or 
“late” treatment subgroups (Chi2 0.2, df 1; p=0.66), see Figure 6.  
Clinical Studies 
Two clinical studies were identified. There was no placebo controlled study. Kemp et al. 
examined the effectiveness of MEL in seven male adults with sleep disturbance and was of 
good methodological quality except for being significantly underpowered 78. The TBI 
ranged from mild to severe and occurred 36 months (range: 9 to 73) previously. A double 
blind randomized crossover study was performed using 5mg of oral MEL in comparison to 
25 mg Amitriptyline for 4 weeks 78. There was no effect of MEL treatment on sleep or 
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neuropsychological parameters compared to the active comparator, Amitriptyline. No 
adverse events were reported.  
Kuczynski et al. reported an open-label retrospective cohort study of children (mean age 
14 years, SD 3.1) with postconcussion syndrome and post traumatic headaches 8 months 
following mild TBI46. Although a beneficial effect of MEL was reported: 75% (95% CI: 49, 
88) had greater than 50% improvement in the number of headaches, the study was 
uncontrolled. The effect on sleep was not reported. No adverse events were reported. 
Caution should be observed when drawing any conclusion from this study due to its low 
methodological quality.  
DISCUSSION 
The goal of this review was to systematically evaluate the literature for the efficacy of 
Melatonin as a potential treatment to improve outcome after TBI. Pre-clinical intervention 
studies, although often focused on a biological construct, ideally have either a pathological 
or behavioural outcome consistent with clinical realities in order to add validity and allow 
clinical correlation.  By necessity pre-clinical studies often have small sample sizes. A 
systematic review combined with meta-analysis allows the data to be methodologically 
and objectively assessed.  This is the first systematic review of the evidence supporting the 
use of MEL in animal models and humans with TBI. Based on the results of our meta-
analysis in pre-clinical studies, there is potential for treatment with MEL to improve 
functional outcome.  
Melatonin significantly improved neurobehavioural outcome in neurological, cognitive, 
and motor domains, as well as histopathological domains (contusion size and cerebral 
oedema). There was an overall positive standardized mean difference of 1.51 (95% CI, 
1.06, 1.96). This is similar to its effect in a systematic review of preclinical stroke models 79 
and meta-analysis of MEL as a treatment for pain in adults 80. Although the results of this 
meta-analysis are strengthened by the effect seen across multiple species (mouse, rat, and 
rabbit), it is significantly weakened by the significant methodological differences, 
especially dose and timing of treatments.  
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After injury, Melatonin was administered within minutes or up to several hours later and 
was used as a single treatment in some and repeated treatment in other studies. Timing 
theoretically could target different mechanisms e.g., early administration affecting 
glutamate toxicity and free radical formation; and later doses targeting neuroinflammation 
13, 21. As secondary brain injury is a rapidly progressive process, especially in the first few 
days, timing of drug administration is likely to be important 4. In humans, MEL achieves 
maximum concentrations around 45 minutes when given orally (2 hours if given 
intravenously), except when slow-release preparations are used (2 hours). And its half-life 
is around 2 hours 57. Here, although earlier treatment was found to be beneficial in one 
larger study 69, we did not find an effect of single versus multiple dosing regimens nor of 
early versus late initiation of treatment in subgroup meta-regression analysis. However, 
the variability of drug dosage (total dose: 2.5mg to 300mg) make these assessments less 
reliable. This is especially relevant as larger doses of MEL result in greater serum 
concentrations, at which supraphysiological non-receptor mediated effects occur (e.g. 
direct free radical scavenging, enhancement of mitochondrial function) 27. For example, 
two studies found MEL 5mg/kg was more effective than 1mg/kg or 2.5mg/kg 69, 74. 
Most pre-clinical studies had moderate or unclear risks of bias. A key factor in this was the 
lack of reporting detail to allow satisfactory experimental evaluation. Further, many 
investigators failed to either randomize or blind assessors and animal carers to the 
treatment condition. No studies provided sample size estimation or published protocols. 
This emphasizes the need for more rigor in applying reporting standards and for the 
publishing of experimental protocols. 
In clinical studies there was a lack of well-designed and adequately powered trials and the 
two studies identified in the review evaluated the use of MEL in the chronic phase of TBI 
recovery for specific symptoms, headache 46 and sleep 78. These were of low quality. The 
randomized controlled crossover trial was significantly underpowered and unlikely to 
detect difference from an active comparator (Amitriptyline) 78. The other clinical study was 
retrospective 46. Overall, although MEL was well tolerated, there was a lack of data to 
support the use of MEL as a neuroprotective agent or for specific symptom management 
in clinical populations. 
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This current study has many strengths. Firstly, it is a systematic review of the current 
evidence and followed a published protocol method to ensure a diligent and rigorous 
review process. By conducting a meta-analysis, studies were combined to increase overall 
sample size and statistical precision. Finally, included studies had functional neurological 
outcomes across the many domains of neurological impairment seen after TBI and so 
clinical inferences can be easily made.  
Although we attempted to be comprehensive, this review may have failed to identify 
studies and also be subject to publication bias. We did not include unpublished data and 
this may have skewed our results. All the studies in this review had small sample sizes and 
when combined with a relative paucity of studies the meta-analysis is limited by a small 
dataset. This systematic review has not investigated dosage or length of treatment beyond 
the first few days. It was not possible to examine the effects of MEL in specific TBI 
populations such as youth and the elderly who may have different response to the 
treatment. Nor were there sufficient studies to allow the evaluation of its use in different 
TBI pathologies e.g. diffuse versus focal injury.  
Conclusions 
There is evidence from pre-clinical studies that Melatonin treatment after TBI significantly 
improves both behavioural outcomes and pathological outcomes, but significant research 
gaps exist. There is insufficient clinical data to support routine use following TBI but further 
clinical research is warranted to evaluate whether Melatonin is a viable and safe 
adjunctive treatment to improve outcome after traumatic brain injury. 
Author Disclosure Statement 
This work was supported by the Alberta Children’s Hospital Foundation Neurotrauma 
Grant (RT34396). Dr. Barlow was supported in part by a tuition scholarship from the 
University of Queensland. There are no conflicts of interest to declare.  
  
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 O
f Q
ue
en
sla
nd
 fr
om
 w
ww
.lie
be
rtp
ub
.co
m 
at 
07
/15
/18
. F
or 
pe
rso
na
l u
se 
on
ly.
 
Page 16 of 50 
 
 
 
16 
Jo
ur
na
l o
f N
eu
ro
tr
au
m
a 
M
el
at
on
in
 a
s a
 tr
ea
tm
en
t a
fte
r T
ra
um
at
ic 
Br
ai
n 
In
ju
ry
: A
 sy
st
em
at
ic 
re
vi
ew
 a
nd
 m
et
a-
an
al
ys
is 
of
 th
e 
pr
e-
cli
ni
ca
l a
nd
 cl
in
ica
l l
ite
ra
tu
re
&
#1
3;
  (
DO
I: 
10
.1
08
9/
ne
u.
20
18
.5
75
2)
 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
References 
 
1. Faul, M., Xu, L., Wald, M. and Coronado, V.G. (2010). Traumatic brain injury in the United 
States: emergency department visits, hospitalizations and deaths 2002–2006. Atlanta, GA: 
Centers for Disease Control and Prevention, National Center for Injury Prevention and 
Control, 2-70. 
2. Feigin, V.L., Theadom A Fau - Barker-Collo, S., Barker-Collo S Fau - Starkey, N.J., Starkey Nj 
Fau - McPherson, K., McPherson K Fau - Kahan, M., Kahan M Fau - Dowell, A., Dowell A Fau 
- Brown, P., Brown P Fau - Parag, V., Parag V Fau - Kydd, R., Kydd R Fau - Jones, K., Jones K 
Fau - Jones, A., Jones A Fau - Ameratunga, S. and Ameratunga, S. Incidence of traumatic 
brain injury in New Zealand: a population-based study. 
3. Carney, N., Totten, A.M., O'Reilly, C., Ullman, J.S., Hawryluk, G.W., Bell, M.J., Bratton, S.L., 
Chesnut, R., Harris, O.A., Kissoon, N., Rubiano, A.M., Shutter, L., Tasker, R.C., Vavilala, M.S., 
Wilberger, J., Wright, D.W. and Ghajar, J. (2017). Guidelines for the Management of Severe 
Traumatic Brain Injury, Fourth Edition. Neurosurgery 80, 6-15. 
4. Prins, M., Greco, T., Alexander, D. and Giza, C.C. (2013). The pathophysiology of 
traumatic brain injury at a glance. Disease models & mechanisms 6, 1307-1315. 
5. Stocchetti, N., Carbonara, M., Citerio, G., Ercole, A., Skrifvars, M.B., Smielewski, P., 
Zoerle, T. and Menon, D.K. (2017). Severe traumatic brain injury: targeted management in 
the intensive care unit. Lancet Neurol 16, 452-464. 
6. Diaz-Arrastia, R., Kochanek, P.M., Bergold, P., Kenney, K., Marx, C.E., Grimes, C.J.B., Loh, 
L.T.C.Y., Adam, L.T.C.G.E., Oskvig, D., Curley, K.C. and Salzer, C.W. (2014). Pharmacotherapy 
of Traumatic Brain Injury: State of the Science and the Road Forward: Report of the 
Department of Defense Neurotrauma Pharmacology Workgroup. Journal of Neurotrauma 
31, 135-158. 
7. Redman, J., Armstrong, S. and Ng, K.T. (1983). Free-running activity rhythms in the rat: 
entrainment by melatonin. Science 219, 1089. 
 
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 O
f Q
ue
en
sla
nd
 fr
om
 w
ww
.lie
be
rtp
ub
.co
m 
at 
07
/15
/18
. F
or 
pe
rso
na
l u
se 
on
ly.
 
Page 17 of 50 
 
 
 
17 
Jo
ur
na
l o
f N
eu
ro
tr
au
m
a 
M
el
at
on
in
 a
s a
 tr
ea
tm
en
t a
fte
r T
ra
um
at
ic 
Br
ai
n 
In
ju
ry
: A
 sy
st
em
at
ic 
re
vi
ew
 a
nd
 m
et
a-
an
al
ys
is 
of
 th
e 
pr
e-
cli
ni
ca
l a
nd
 cl
in
ica
l l
ite
ra
tu
re
&
#1
3;
  (
DO
I: 
10
.1
08
9/
ne
u.
20
18
.5
75
2)
 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
8. Redman, J.R. and Armstrong, S.M. (1988). Reentrainment of rat circadian activity 
rhythms: effects of melatonin. J Pineal Res 5, 203-215. 
9. Herrera, E.A., Macchiavello, R., Montt, C., Ebensperger, G., Diaz, M., Ramirez, S., Parer, 
J.T., Seron-Ferre, M., Reyes, R.V. and Llanos, A.J. (2014). Melatonin improves 
cerebrovascular function and decreases oxidative stress in chronically hypoxic lambs. 
Journal of Pineal Research 57, 33-42. 
10. Aly, H., Elmahdy, H., El-Dib, M., Rowisha, M., Awny, M., El-Gohary, T., Elbatch, M., 
Hamisa, M. and El-Mashad, A.R. (2015). Melatonin use for neuroprotection in perinatal 
asphyxia: a randomized controlled pilot study. Journal of Perinatology 35, 186-191. 
11. Chumboatong, W., Thummayot, S., Govitrapong, P., Tocharus, C., Jittiwat, J. and Tocharus, 
J. (2017). Neuroprotection of agomelatine against cerebral ischemia/reperfusion injury 
through an antiapoptotic pathway in rat. Neurochemistry International 102, 114-122. 
12. Herrera, F., Sainz, R.M., Mayo, J.C., Martín, V., Antolín, I. and Rodriguez, C. (2001). 
Glutamate induces oxidative stress not mediated by glutamate receptors or cystine 
transporters: protective effect of melatonin and other antioxidants. Journal of pineal 
research 31, 356-362. 
13. Esposito, E. and Cuzzocrea, S. (2010). Antiinflammatory activity of melatonin in central 
nervous system. Current neuropharmacology 8, 228. 
14. Fernández-Gajardo, R., Matamala, J.M., Carrasco, R., Gutiérrez, R., Melo, R. and 
Rodrigo, R. (2014). Novel therapeutic strategies for traumatic brain injury: acute 
antioxidant reinforcement. CNS drugs 28, 229-248. 
15. Maldonado, M.D., Murillo-Cabezas, F., Terron, M.P., Flores, L.J., Tan, D.X., Manchester, 
L.C. and Reiter, R.J. (2007). The potential of melatonin in reducing morbidity-mortality after 
craniocerebral trauma. J Pineal Res 42, 1-11. 
16. Hardeland, R., Cardinali, D.P., Srinivasan, V., Spence, D.W., Brown, G.M. and Pandi-
Perumal, S.R. (2011). Melatonin--a pleiotropic, orchestrating regulator molecule. Progress 
in neurobiology 93, 350-384. 
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 O
f Q
ue
en
sla
nd
 fr
om
 w
ww
.lie
be
rtp
ub
.co
m 
at 
07
/15
/18
. F
or 
pe
rso
na
l u
se 
on
ly.
 
Page 18 of 50 
 
 
 
18 
Jo
ur
na
l o
f N
eu
ro
tr
au
m
a 
M
el
at
on
in
 a
s a
 tr
ea
tm
en
t a
fte
r T
ra
um
at
ic 
Br
ai
n 
In
ju
ry
: A
 sy
st
em
at
ic 
re
vi
ew
 a
nd
 m
et
a-
an
al
ys
is 
of
 th
e 
pr
e-
cli
ni
ca
l a
nd
 cl
in
ica
l l
ite
ra
tu
re
&
#1
3;
  (
DO
I: 
10
.1
08
9/
ne
u.
20
18
.5
75
2)
 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
17. Luchetti, F., Canonico, B., Betti, M., Arcangeletti, M., Pilolli, F., Piroddi, M., Canesi, L., 
Papa, S. and Galli, F. (2010). Melatonin signaling and cell protection function. FASEB J 24, 
3603-3624. 
18. Reiter, R.J., Tan, D.-X. and Fuentes-Broto, L. (2010). Melatonin: a multitasking molecule. 
Prog Brain Res 181, 127-151. 
19. Becker-André, M., Wiesenberg, I., Schaeren-Wiemers, N., André, E., Missbach, M., 
Saurat, J.H. and Carlberg, C. (1994). Pineal gland hormone melatonin binds and activates an 
orphan of the nuclear receptor superfamily. J Biol Chem 269, 28531-28534. 
20. Leon, J., Acuña-Castroviejo, D., Sainz, R.M., Mayo, J.C., Tan, D.X. and Reiter, R.J. (2004). 
Melatonin and mitochondrial function. Life sciences 75, 765-790. 
21. Tan, D.-X., Manchester, L.C., Terron, M.P., Flores, L.J. and Reiter, R.J. (2007). One 
molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen 
and nitrogen species? J Pineal Res 42, 28-42. 
22. Allegra, M., Reiter, R.J., Tan, D.-X., Gentile, C., Tesoriere, L. and Livrea, M.A. (2003). The 
chemistry of melatonin's interaction with reactive species. J Pineal Res 34, 1-10. 
23. Rosen, J., Than, N.N., Koch, D., Poeggeler, B., Laatsch, H. and Hardeland, R. (2006). 
Interactions of melatonin and its metabolites with the ABTS cation radical: extension of the 
radical scavenger cascade and formation of a novel class of oxidation products, C2-
substituted 3-indolinones. J Pineal Res 41, 374-381. 
24. Tan, D.X., Manchester, L.C., Reiter, R.J., Qi, W.B., Karbownik, M. and Calvo, J.R. (2000). 
Significance of melatonin in antioxidative defense system: reactions and products. Biol 
Signals Recept 9, 137-159. 
25. Rodriguez, C., Mayo, J.C., Sainz, R.M., Antolín, I., Herrera, F., Martín, V. and Reiter, R.J. 
(2004). Regulation of antioxidant enzymes: a significant role for melatonin. Journal of 
pineal research 36, 1-9. 
 
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 O
f Q
ue
en
sla
nd
 fr
om
 w
ww
.lie
be
rtp
ub
.co
m 
at 
07
/15
/18
. F
or 
pe
rso
na
l u
se 
on
ly.
 
Page 19 of 50 
 
 
 
19 
Jo
ur
na
l o
f N
eu
ro
tr
au
m
a 
M
el
at
on
in
 a
s a
 tr
ea
tm
en
t a
fte
r T
ra
um
at
ic 
Br
ai
n 
In
ju
ry
: A
 sy
st
em
at
ic 
re
vi
ew
 a
nd
 m
et
a-
an
al
ys
is 
of
 th
e 
pr
e-
cli
ni
ca
l a
nd
 cl
in
ica
l l
ite
ra
tu
re
&
#1
3;
  (
DO
I: 
10
.1
08
9/
ne
u.
20
18
.5
75
2)
 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
26. Acuña Castroviejo, D., López, L.C., Escames, G., López, A., García, J.A. and Reiter, R.J. 
(2011). Melatonin-mitochondria interplay in health and disease. Curr Top Med Chem 11, 
221-240. 
27. Acuña-Castroviejo, D., Escames, G., León, J., Carazo, A. and Khaldy, H. (2003). 
Mitochondrial regulation by melatonin and its metabolites. Adv Exp Med Biol 527, 549-
557. 
28. León, J., Acuña-Castroviejo, D., Escames, G., Tan, D.-X. and Reiter, R.J. (2005). Melatonin 
mitigates mitochondrial malfunction. J Pineal Res 38, 1-9. 
29. Hu, Y., Wang, Z., Liu, Y., Pan, S., Zhang, H., Fang, M., Jiang, H., Yin, J., Zou, S., Li, Z., 
Zhang, H., Lin, Z. and Xiao, J. (2017). Melatonin reduces hypoxic-ischaemic (HI) induced 
autophagy and apoptosis: An in vivo and in vitro investigation in experimental models of 
neonatal HI brain injury. Neuroscience Letters 653, 105-112. 
30. Wu, H., Shao, A., Zhao, M., Chen, S., Yu, J., Zhou, J., Liang, F., Shi, L., Dixon, B.J., Wang, 
Z., Ling, C., Hong, Y. and Zhang, J. (2016). Melatonin attenuates neuronal apoptosis through 
up-regulation of K(+) -Cl(-) cotransporter KCC2 expression following traumatic brain injury 
in rats. Journal of Pineal Research 61, 241-250. 
31. Das, A., McDowell, M., Pava, M.J., Smith, J.A., Reiter, R.J., Woodward, J.J., Varma, A.K., 
Ray, S.K. and Banik, N.L. (2010). The inhibition of apoptosis by melatonin in VSC4.1 
motoneurons exposed to oxidative stress, glutamate excitotoxicity, or TNF-alpha toxicity 
involves membrane melatonin receptors. J Pineal Res 48, 157-169. 
32. Hovda, D.A., Lee, S.M., Smith, M.L., Von Stuck, S., Bergsneider, M., Kelly, D., Shalmon, 
E., Martin, N., Caron, M., Mazziotta, J. and et al. (1995). The neurochemical and metabolic 
cascade following brain injury: moving from animal models to man. J Neurotrauma 12, 
903-906. 
33. Scott, F.F., Belle, M.D.C., Delagrange, P. and Piggins, H.D. (2010). Electrophysiological 
effects of melatonin on mouse Per1 and non-Per1 suprachiasmatic nuclei neurones in vitro. 
J Neuroendocrinol 22, 1148-1156. 
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 O
f Q
ue
en
sla
nd
 fr
om
 w
ww
.lie
be
rtp
ub
.co
m 
at 
07
/15
/18
. F
or 
pe
rso
na
l u
se 
on
ly.
 
Page 20 of 50 
 
 
 
20 
Jo
ur
na
l o
f N
eu
ro
tr
au
m
a 
M
el
at
on
in
 a
s a
 tr
ea
tm
en
t a
fte
r T
ra
um
at
ic 
Br
ai
n 
In
ju
ry
: A
 sy
st
em
at
ic 
re
vi
ew
 a
nd
 m
et
a-
an
al
ys
is 
of
 th
e 
pr
e-
cli
ni
ca
l a
nd
 cl
in
ica
l l
ite
ra
tu
re
&
#1
3;
  (
DO
I: 
10
.1
08
9/
ne
u.
20
18
.5
75
2)
 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
34. Paula-Lima, A.C., Louzada, P.R., De Mello, F.G. and Ferreira, S.T. (2003). Neuroprotection 
against Abeta and glutamate toxicity by melatonin: are GABA receptors involved? Neurotox 
Res 5, 323-327. 
35. Matsuta, Y., Yusup, A., Tanase, K., Ishida, H., Akino, H. and Yokoyama, O. (2010). 
Melatonin increases bladder capacity via GABAergic system and decreases urine volume in 
rats. J Urol 184, 386-391. 
36. Cheng, X.-P., Sun, H., Ye, Z.-Y. and Zhou, J.-N. (2012). Melatonin modulates the 
GABAergic response in cultured rat hippocampal neurons. J Pharmacol Sci 119, 177-185. 
37. Andrews-Zwilling, Y., Bien-Ly, N., Xu, Q., Li, G., Bernardo, A., Yoon, S.Y., Zwilling, D., Yan, 
T.X., Chen, L. and Huang, Y. (2010). Apolipoprotein E4 causes age- and Tau-dependent 
impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J 
Neurosci 30, 13707-13717. 
38. Cherry, J.D., Tripodis, Y., Alvarez, V.E., Huber, B., Kiernan, P.T., Daneshvar, D.H., Mez, J., 
Montenigro, P.H., Solomon, T.M., Alosco, M.L., Stern, R.A., McKee, A.C. and Stein, T.D. 
(2016). Microglial neuroinflammation contributes to tau accumulation in chronic traumatic 
encephalopathy. Acta Neuropathologica Communications 4, 112. 
39. Villapol, S., Fau, S., Renolleau, S., Biran, V., Charriaut-Marlangue, C. and Baud, O. 
(2011). Melatonin promotes myelination by decreasing white matter inflammation after 
neonatal stroke. Pediatric Research 69, 51-55. 
40. Campolo, M., Ahmad, A., Crupi, R., Impellizzeri, D., Morabito, R., Esposito, E. and 
Cuzzocrea, S. (2013). Combination therapy with melatonin and dexamethasone in a mouse 
model of traumatic brain injury. Journal of Endocrinology 217, 291-301. 
41. Tsai, M.C., Chen, W.J., Tsai, M.S., Ching, C.H. and Chuang, J.I. (2011). Melatonin 
attenuates brain contusion-induced oxidative insult, inactivation of signal transducers and 
activators of transcription 1, and upregulation of suppressor of cytokine signaling-3 in rats. 
J Pineal Res 51, 233-245. 
42. Bramley, H., Henson, A., Lewis, M.M., Kong, L., Stetter, C. and Silvis, M. (2017). Sleep 
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 O
f Q
ue
en
sla
nd
 fr
om
 w
ww
.lie
be
rtp
ub
.co
m 
at 
07
/15
/18
. F
or 
pe
rso
na
l u
se 
on
ly.
 
Page 21 of 50 
 
 
 
21 
Jo
ur
na
l o
f N
eu
ro
tr
au
m
a 
M
el
at
on
in
 a
s a
 tr
ea
tm
en
t a
fte
r T
ra
um
at
ic 
Br
ai
n 
In
ju
ry
: A
 sy
st
em
at
ic 
re
vi
ew
 a
nd
 m
et
a-
an
al
ys
is 
of
 th
e 
pr
e-
cli
ni
ca
l a
nd
 cl
in
ica
l l
ite
ra
tu
re
&
#1
3;
  (
DO
I: 
10
.1
08
9/
ne
u.
20
18
.5
75
2)
 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
Disturbance Following Concussion Is a Risk Factor for a Prolonged Recovery. Clin Pediatr 
(Phila) 56, 1280-1285. 
43. Dong, Y., Sheng, P., Tong, W., Li, Z., Xu, D. and Hou, L. (2013). Risk factors associated 
with sleep disturbance following traumatic brain injury. Sleep Medicine Conference, 5th 
International World Association of Sleep Medicine Congress and the 22nd Annual Congress 
of the Spanish Sleep Society Valencia Spain. Conference Start: 20130928 Conference End: 
20131002. Conference Publication: (var.pagings). 20130914 (pp e20130109). 
44. Ponsford, J.L., Ziino, C., Parcell, D.L., Shekleton, J.A., Roper, M., Redman, J.R., Phipps-Nelson, 
J. and Rajaratnam, S.M. (2012). Fatigue and sleep disturbance following traumatic brain injury--
their nature, causes, and potential treatments. J Head Trauma Rehabil 27, 224-233. 
45. Barlow, K.M. (2016). Postconcussion Syndrome: A Review. J Child Neurol 31, 57-67. 
46. Kuczynski, A., Crawford, S., Bodell, L., Dewey, D. and Barlow, K.M. (2013). 
Characteristics of post-traumatic headaches in children following mild traumatic brain 
injury and their response to treatment: a prospective cohort. Developmental Medicine and 
Child Neurology 55, 636-641. 
47. Max, J.E., Lopez, A., Wilde, E.A., Bigler, E.D., Schachar, R.J., Saunders, A., Ewing-Cobbs, 
L., Chapman, S.B., Yang, T.T. and Levin, H.S. (2015). Anxiety disorders in children and 
adolescents in the second six months after traumatic brain injury. J Pediatr Rehabil Med 8, 
345-355. 
48. Dodge, N.N. and Wilson, G.A. (2001). Melatonin for treatment of sleep disorders in 
children with developmental disabilities. Journal of child neurology 16, 581-584. 
49. Dai, X., Cui, S., Li, S., Chen, Q. and Wang, R. (2007). Melatonin attenuates the 
development of antinociceptive tolerance to delta-, but not to mu-opioid receptor agonist 
in mice. Behavioural brain research 182, 21-27. 
50. Wilhelmsen, M., Amirian, I., Reiter, R.J., Rosenberg, J. and Gögenur, I. (2011). Analgesic 
effects of melatonin: a review of current evidence from experimental and clinical studies. J 
Pineal Res 51, 270-277. 
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 O
f Q
ue
en
sla
nd
 fr
om
 w
ww
.lie
be
rtp
ub
.co
m 
at 
07
/15
/18
. F
or 
pe
rso
na
l u
se 
on
ly.
 
Page 22 of 50 
 
 
 
22 
Jo
ur
na
l o
f N
eu
ro
tr
au
m
a 
M
el
at
on
in
 a
s a
 tr
ea
tm
en
t a
fte
r T
ra
um
at
ic 
Br
ai
n 
In
ju
ry
: A
 sy
st
em
at
ic 
re
vi
ew
 a
nd
 m
et
a-
an
al
ys
is 
of
 th
e 
pr
e-
cli
ni
ca
l a
nd
 cl
in
ica
l l
ite
ra
tu
re
&
#1
3;
  (
DO
I: 
10
.1
08
9/
ne
u.
20
18
.5
75
2)
 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
51. Peres, M.F.P., Zukerman, E., da Cunha Tanuri, F., Moreira, F.R. and Cipolla-Neto, J. 
(2004). Melatonin, 3 mg, is effective for migraine prevention. Neurology 63, 757. 
52. Miano, S., Parisi, P., Pelliccia, A., Luchetti, A., Paolino, M.C. and Villa, M.P. (2008). 
Melatonin to prevent migraine or tension-type headache in children. Neurological sciences 
29, 285-287. 
53. Citera, G., Arias, M.A., Maldonado-Cocco, J.A., Lázaro, M.A., Rosemffet, M.G., Brusco, 
L.I., Scheines, E.J. and Cardinalli, D.P. (2000). The effect of melatonin in patients with 
fibromyalgia: a pilot study. Clin Rheumatol 19, 9-13. 
54. Mozaffari, S., Rahimi, R. and Abdollahi, M. (2010). Implications of melatonin therapy in 
irritable bowel syndrome: a systematic review. Curr Pharm Des 16, 3646-3655. 
55. Dominguez-Rodriguez, A., Abreu-Gonzalez, P., de la Torre-Hernandez, J.M., Gonzalez-
Gonzalez, J., Garcia-Camarero, T., Consuegra-Sanchez, L., Garcia-Saiz, M.D., Aldea-Perona, 
A., Virgos-Aller, T., Azpeitia, A. and Reiter, R.J. (2017). Effect of intravenous and 
intracoronary melatonin as an adjunct to primary percutaneous coronary intervention for 
acute ST-elevation myocardial infarction: Results of the Melatonin Adjunct in the acute 
myocaRdial Infarction treated with Angioplasty trial. J Pineal Res 62. 
56. Gringras, P., Nir, T., Breddy, J., Frydman-Marom, A. and Findling, R.L. (2017). Efficacy 
and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism 
Spectrum Disorder. J Am Acad Child Adolesc Psychiatry 56, 948-957.e944. 
57. Harpsøe, N.G., Andersen, L.P.H., Gögenur, I. and Rosenberg, J. (2015). Clinical 
pharmacokinetics of melatonin: a systematic review. European Journal of Clinical 
Pharmacology 71, 901-909. 
58. Zeng, X., Zhang, Y., Kwong, J.S., Zhang, C., Li, S., Sun, F., Niu, Y. and Du, L. (2015). The 
methodological quality assessment tools for preclinical and clinical studies, systematic 
review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based 
Med 8, 2-10. 
 
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 O
f Q
ue
en
sla
nd
 fr
om
 w
ww
.lie
be
rtp
ub
.co
m 
at 
07
/15
/18
. F
or 
pe
rso
na
l u
se 
on
ly.
 
Page 23 of 50 
 
 
 
23 
Jo
ur
na
l o
f N
eu
ro
tr
au
m
a 
M
el
at
on
in
 a
s a
 tr
ea
tm
en
t a
fte
r T
ra
um
at
ic 
Br
ai
n 
In
ju
ry
: A
 sy
st
em
at
ic 
re
vi
ew
 a
nd
 m
et
a-
an
al
ys
is 
of
 th
e 
pr
e-
cli
ni
ca
l a
nd
 cl
in
ica
l l
ite
ra
tu
re
&
#1
3;
  (
DO
I: 
10
.1
08
9/
ne
u.
20
18
.5
75
2)
 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
59. Downs, S.H. and Black, N. (1998). The feasibility of creating a checklist for the 
assessment of the methodological quality both of randomised and non-randomised studies 
of health care interventions. J Epidemiol Community Health 52, 377-384. 
60. Ates, O., Cayli, S., Gurses, I., Yucel, N., Iraz, M., Altinoz, E., Kocak, A. and Yologlu, S. 
(2006). Effect of pinealectomy and melatonin replacement on morphological and 
biochemical recovery after traumatic brain injury. International Journal of Developmental 
Neuroscience 24, 357-363. 
61. Bayir, A., Kiresi, D.A., Kara, H., Cengiz, S.L., Kocak, S., Ozdinc, S., Ak, A. and Bodur, S. 
(2008). The effects of mannitol and melatonin on MRI findings in an animal model of 
traumatic brain edema. Acta Neurologica Belgica 108, 149-154. 
62. Beni, S.M., Kohen, R., Reiter, R.J., Tan, D.X. and Shohami, E. (2004). Melatonin-induced 
neuroprotection after closed head injury is associated with increased brain antioxidants 
and attenuated late-phase activation of NF-kappaB and AP-1. FASEB J 18, 149-151. 
63. Dehghan, F., Khaksari Hadad, M., Asadikram, G., Najafipour, H. and Shahrokhi, N. 
(2013). Effect of melatonin on intracranial pressure and brain edema following traumatic 
brain injury: role of oxidative stresses. Archives of Medical Research 44, 251-258. 
64. Ding, K., Wang, H., Xu, J., Lu, X., Zhang, L. and Zhu, L. (2014). Melatonin reduced 
microglial activation and alleviated neuroinflammation induced neuron degeneration in 
experimental traumatic brain injury: Possible involvement of mTOR pathway. 
Neurochemistry International 76, 23-31. 
65. Ding, K., Xu, J., Wang, H., Zhang, L., Wu, Y. and Li, T. (2015). Melatonin protects the 
brain from apoptosis by enhancement of autophagy after traumatic brain injury in mice. 
Neurochemistry International 91, 46-54. 
66. Kabadi, S.V. and Maher, T.J. (2010). Posttreatment with uridine and melatonin following 
traumatic brain injury reduces edema in various brain regions in rats. Annals of the New 
York Academy of Sciences 1199, 105-113. 
67. Kelso, M.L., Scheff, N.N., Scheff, S.W. and Pauly, J.R. (2011). Melatonin and minocycline 
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 O
f Q
ue
en
sla
nd
 fr
om
 w
ww
.lie
be
rtp
ub
.co
m 
at 
07
/15
/18
. F
or 
pe
rso
na
l u
se 
on
ly.
 
Page 24 of 50 
 
 
 
24 
Jo
ur
na
l o
f N
eu
ro
tr
au
m
a 
M
el
at
on
in
 a
s a
 tr
ea
tm
en
t a
fte
r T
ra
um
at
ic 
Br
ai
n 
In
ju
ry
: A
 sy
st
em
at
ic 
re
vi
ew
 a
nd
 m
et
a-
an
al
ys
is 
of
 th
e 
pr
e-
cli
ni
ca
l a
nd
 cl
in
ica
l l
ite
ra
tu
re
&
#1
3;
  (
DO
I: 
10
.1
08
9/
ne
u.
20
18
.5
75
2)
 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
for combinatorial therapy to improve functional and histopathological deficits following 
traumatic brain injury. Neuroscience Letters 488, 60-64. 
68. Lin, C., Chao, H., Li, Z., Xu, X., Liu, Y., Hou, L., Liu, N. and Ji, J. (2016). Melatonin 
attenuates traumatic brain injury-induced inflammation: a possible role for mitophagy. 
Journal of Pineal Research 61, 177-186. 
69. Mesenge, C., Margaill, I., Verrecchia, C., Allix, M., Boulu, R.G. and Plotkine, M. (1998). 
Protective effect of melatonin in a model of traumatic brain injury in mice. Journal of Pineal 
Research 25, 41-46. 
70. Ozdemir, D., Tugyan, K., Uysal, N., Sonmez, U., Sonmez, A., Acikgoz, O., Ozdemir, N., 
Duman, M. and Ozkan, H. (2005). Protective effect of melatonin against head trauma-
induced hippocampal damage and spatial memory deficits in immature rats. Neuroscience 
Letters 385, 234-239. 
71. Sarrafzadeh, A.S., Thomale, U.W., Kroppenstedt, S.N. and Unterberg, A.W. (2000). 
Neuroprotective effect of melatonin on cortical impact injury in the rat. Acta 
Neurochirurgica 142, 1293-1299. 
72. Yamakawa, G.R., Salberg, S., Barlow, K.M., Brooks, B.L., Esser, M.J., Yeates, K.O. and 
Mychasiuk, R. (2017). Manipulating cognitive reserve: Pre-injury environmental conditions 
influence the severity of concussion symptomology, gene expression, and response to 
melatonin treatment in rats. Experimental Neurology 295, 55-65. 
73. Kemp, S., Biswas, R., Neumann, V. and Coughlan, A. (2004). The value of melatonin for 
sleep disorders occurring post-head injury: a pilot RCT. Brain injury : [BI] 18, 911-919. 
74. Beni, S.M., Kohen, R., Reiter, R.J., Tan, D.X. and Shohami, E. (2004). Melatonin-induced 
neuroprotection after closed head injury is associated with increased brain antioxidants 
and attenuated late-phase activation of NF-kappaB and AP-1. FASEB Journal 18, 149-151. 
75. Kabadi, S.V. and Maher, T.J. (2010). Posttreatment with uridine and melatonin following 
traumatic brain injury reduces edema in various brain regions in rats. Ann N Y Acad Sci 
1199, 105-113. 
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 O
f Q
ue
en
sla
nd
 fr
om
 w
ww
.lie
be
rtp
ub
.co
m 
at 
07
/15
/18
. F
or 
pe
rso
na
l u
se 
on
ly.
 
Page 25 of 50 
 
 
 
25 
Jo
ur
na
l o
f N
eu
ro
tr
au
m
a 
M
el
at
on
in
 a
s a
 tr
ea
tm
en
t a
fte
r T
ra
um
at
ic 
Br
ai
n 
In
ju
ry
: A
 sy
st
em
at
ic 
re
vi
ew
 a
nd
 m
et
a-
an
al
ys
is 
of
 th
e 
pr
e-
cli
ni
ca
l a
nd
 cl
in
ica
l l
ite
ra
tu
re
&
#1
3;
  (
DO
I: 
10
.1
08
9/
ne
u.
20
18
.5
75
2)
 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
76. Kabadi, S.V. and Maher, T.J. (2009). Effect of uridine (U), melatonin (MLT) and ramelteon 
(RMT) on edema formation following traumatic brain injury (TBI) in rats. The FASEB Journal 
23. 
77. Kochanek, P.M., Carney, N., Adelson, P.D., Ashwal, S., Bell, M.J., Bratton, S., Carson, S., 
Chesnut, R.M., Ghajar, J., Goldstein, B., Grant, G.A., Kissoon, N., Peterson, K., Selden, N.R., 
Tasker, R.C., Tong, K.A., Vavilala, M.S., Wainwright, M.S., Warden, C.R., American Academy 
of Pediatrics-Section on Neurological, S., American Association of Neurological 
Surgeons/Congress of Neurological, S., Child Neurology, S., European Society of, P., 
Neonatal Intensive, C., Neurocritical Care, S., Pediatric Neurocritical Care Research, G., 
Society of Critical Care, M., Paediatric Intensive Care Society, U.K., Society for Neuroscience 
in, A., Critical, C., World Federation of Pediatric, I. and Critical Care, S. (2012). Guidelines 
for the acute medical management of severe traumatic brain injury in infants, children, and 
adolescents--second edition. Pediatr Crit Care Med 13 Suppl 1, S1-82. 
78. Kemp, S., Biswas, R., Neumann, V. and Coughlan, A. (2004). The value of melatonin for 
sleep disorders occurring post-head injury: a pilot RCT. Brain Inj 18, 911-919. 
79. O'Collins, V.E., Macleod, M.R., Cox, S.F., Van Raay, L., Aleksoska, E., Donnan, G.A. and 
Howells, D.W. (2011). Preclinical drug evaluation for combination therapy in acute stroke 
using systematic review, meta-analysis, and subsequent experimental testing. Journal of 
Cerebral Blood Flow & Metabolism 31, 962-975. 
80. Zhu, C., Xu, Y., Duan, Y., Li, W., Zhang, L., Huang, Y., Zhao, W., Wang, Y., Li, J., Feng, T., Li, 
X., Hu, X. and Yin, W. (2017). Exogenous melatonin in the treatment of pain: a systematic 
review and meta-analysis. Oncotarget 8, 100582-100592. 
 
  
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 O
f Q
ue
en
sla
nd
 fr
om
 w
ww
.lie
be
rtp
ub
.co
m 
at 
07
/15
/18
. F
or 
pe
rso
na
l u
se 
on
ly.
 
Page 26 of 50 
 
 
 
26 
J
o
u
r
n
a
l
 
o
f
 
N
e
u
r
o
t
r
a
u
m
a
 
e
n
t
 
a
f
t
e
r
 
T
r
a
u
m
a
t
i
c
 
B
r
a
i
n
 
I
n
j
u
r
y
:
 
A
 
s
y
s
t
e
m
a
t
i
c
 
r
e
v
i
e
w
 
a
n
d
 
m
e
t
a
-
a
n
a
l
y
s
i
s
 
o
f
 
t
h
e
 
p
r
e
-
c
l
i
n
i
c
a
l
 
a
n
d
 
c
l
i
n
i
c
a
l
 
l
i
t
e
r
a
t
u
r
e
&
#
1
3
;
 
 
(
D
O
I
:
 
1
0
.
1
0
8
9
/
n
e
u
.
2
0
1
8
.
5
7
5
2
)
 
r
e
v
i
e
w
e
d
 
a
n
d
 
a
c
c
e
p
t
e
d
 
f
o
r
 
p
u
b
l
i
c
a
t
i
o
n
,
 
b
u
t
 
h
a
s
 
y
e
t
 
t
o
 
u
n
d
e
r
g
o
 
c
o
p
y
e
d
i
t
i
n
g
 
a
n
d
 
p
r
o
o
f
 
c
o
r
r
e
c
t
i
o
n
.
 
T
h
e
 
f
i
n
a
l
 
p
u
b
l
i
s
h
e
d
 
v
e
r
s
i
o
n
 
m
a
y
 
d
i
f
f
e
r
 
f
r
o
m
 
t
h
i
s
 
p
r
o
o
f
.
 
Table 1: TBI model, study design and quality assessment of included studies 
Study 
 
TBI Model Animal Age Sex Weight Design 
Treated
(n) 
Control
(n) 
QA 
score 
Ates 
2006(60) 
 
CCI 
Rat 1 Adult M 200–250g RCT 12 12 17 
Bayir 
2008(61) 
CHI Rabbit 2 Adult 
MF 
(7,5) 
2000-2500g CT 6 6 16 
Beni 2004 
(62) 
CHI  
mod/severe 
TBI 
Mouse 3 
 
Adult M 30-42g CT 
10 
(7 path)
23 
(7 
path) 
16 
Campolo 
2013(40)  
CCI Mouse 4 Adult M 
25–30g 
 
RCT 10 10 15 
Dehghan 
2013(63)  
Marmarou 
severe TBI 
Rat 5 Adult M 250-300g RCT 7 7 14 
Ding 
2014(64)  
Weight drop 
Mouse 6 
 
Adult M 28–32g CT 
10, 
(6 path)
10,
(6 
path) 
15 
Ding 
2015(65) 
Marmarou Mouse 6 Adult M 28–32g CT 5 5 17 
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Kabadi 
2010(66) 
Fluid 
percussion 
Rat7 Adult M 300–350g CT 7-8 9 16 
Kelso 
2011(67) 
CCI Rat7 Adult M 225–275g RCT 4 4 16 
Lin 2016(68) CCI Rat7 Adult M 220–250g RCT 
10 
(5 path)
10 
(5 
path) 
17 
Mesenge 
1998(69) 
CHI 
Weight drop 
Mouse 8 
 
Adult M 25-30g RCT 14-16 16 13 
Ozdemir 
2005(70) 
CHI 
Weight drop 
Rat 1 Juvenile MF Age: P7 CT 7 7 17 
Sarrafzadeh  
2000(71) 
CCI 
moderate TBI 
Rat7 Adult M Mean: 300g RCT 7 7-8 13 
Wu 2016(30)  CCI Rat7 Adult M 300–330g RCT 12 12 13 
Yamakawa 
2017(72) 
mTBI  
accel/decal 
Rat7 Juvenile MF Age: P30 RCT 5 5 15 
Human 
studies 
 Setting Population  
Mean Age 
(years) 
    
Kemp TBI severity:  Community Adults with  M 39.4  Double-blind 7 7 19/29*
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2004(73) mild (2), 
moderate (3), 
severe (2) 
rehabilitation 
program 
sleep problems (range: 17-
55) 
crossover 
RCT 
Kuczynski 
2013(46) 
Mild TBI 
Tertiary  
concussion  
clinic 
Children with  
post-traumatic 
headaches 
66% F 
14.1  
(SD 3.1) 
Retrospective 
cohort study 
12 32 11/29*
Animal species: 1Albino Wistar rat; 2New Zealand rabbit; 3Sabra mouse; 4CD1 mouse; 5Albino N-Mary rat; 6ICR mouse; 7Sprague-Dawley rat; 
8Swiss mouse 
TBI models: Controlled Cortical Impact (CCI); Closed Head Injury (CHI); Marmarou method (diffuse injury); Fluid percussion; 
Acceleration/deceleration model (Accel/decal) 
Study designs: Randomized Controlled Trial (RCT); Controlled trial (CT); Pathology (path); Male (M); Female (F 
Quality assessment (QA) SYRCLE risk of bias tool; *Downs and Black criteria 
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Table 2: Details of intervention  
Study Treatment 
Dose 
(mg/kg) 
Total dose 
(mg/kg) 
Control Time post-injury Route
Treated
(n) 
Control 
(n) 
Ates 
2006(60) 
MEL 100 100 TBI alone Immediately IP 12 12 
Bayir 
2008(61) 
MEL 100 100 
Mannitol 
20% 2gm/kg 
4h IP 6 6 
Beni 2004 
(62) 
MEL 
 
1 1 
Vehicle 
(5% ethanol) 
1h IP 
10 
23 5 5 23 
10 10 8
Campolo 
2013(40) 
MEL 10 20 
Vehicle 
(1% ethanol) 
1h + 6h IP 10 10 
Dehghan 
2013(63) 
 
MEL 
5 20
Vehicle 
(ethanol) 
1+ 24+ 48 +72h IP 
7 7
20 80 7 7 
Ding 
2014(64) 
 
MEL 10 50 
Vehicle 
(5% ethanol) 
Immed + 1 + 2 + 3 + 4h IP 10 10 
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Ding 
2015(65) 
MEL 10 50 
Vehicle 
(5% ethanol) 
Immed + 1 + 2 + 3 + 4h IP 6 6 
Kabadi 
2010(66) 
MEL 
100 100 Vehicle 
(PEG) 
immediately IP 
7-8 
9 
200 200 7-8 
Kelso 
2011(67) 
MEL 5 10 
Vehicle 
(2% ethanol) 
5min +1h 
 
IP 4 4 
Lin 2016 (68)  MEL 5ml/kg 15ml/kg 
Vehicle 
(2% ethanol) 
Immed + 2 + 4h IP 10 10 
Mesenge 
1998 (69) 
MEL 
(Pilot I) 
1.25 5 Vehicle 
(HCl) 
Ia 20min pre-injury + 
5min + 1+ 2h 
IP 14 
16 
1.25 5 Ib 5min +1+ 2+ 3h IP 15 
MEL 
(Therapeutic 
window II) 
1.25 5 
Vehicle 
(HCl) 
IIa 5min +1+ 2+ 3h IP 15 
13 1.25 5 IIb 30min +1+ 2+ 3h IP 15 
1.25 5 IIc. 1+ 2+ 3 + 4h IP 15 
MEL 
(Dose finding III)  
0.625, 1.25, 
or 2.5 
2.5, 5, 
or 10 
Vehicle 
(HCl) 
5min, 1+ 2+ 3h IP 
15 each 
dose 
13 
Ozdemir 
2005 (70) 
MEL 5 5 
Vehicle  
(5% ethanol) 
immediately IP 7 7 
Sarrafzadeh  MEL 100 300 Vehicle  Day: Immed + 1 + 2h IP 7 7-8 
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2000 (71)  
100  
(0.1% 
ethanol) 
Night: Immed + 1 + 2h 7 7-8 
Wu 2016 (30) MEL 10 50 
Vehicle 
(1% ethanol) 
Immed + 1, 2, 3, and 4h IP 12 12 
Yamakawa 
2017 (72)  
MEL 4.5 4.5 
Vehicle 
(ethanol) 
Day 1-14 Oral 5 5 
Human studies 
Kemp 
2004(73) 
MEL 
5mg orally at 
night 
- AMIT 25mg 
Cross over trial: 
1st arm: 4 weeks, 
washout period: 2 weeks 
2nd arm:4 weeks 
Oral 7 7 
Kuczynski 
2013(46) 
MEL 3 to 10 mg - 
AMT 10-
50mg; other 
treatments 
MEL at night for 4 weeks 
Or 
AMT at night or other 
treatment for 8weeks 
Oral 12 
AMT 18; 
other 14 
 
Melatonin (MEL); Immediately (immed); Hydrogen chloride (HCl); Polyethylene glycol (PEG); Amitriptyline (AMT)  
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Table 3: Details of outcome measures 
Study Outcome measure Function Scale and Direction Time assessed 
Contusion/Traumatic lesion size 
Ates 2006(60) Contusion volume, % 
Quantitative digital analysis of the lesion size 
(5mm section, % ipsilateral hemisphere) 
0-100% 
Lower score is more 
favorable outcome 
14 days 
Beni 2004 (62) Contusion size, % 
Quantitative digital analysis of lesion, (1mm 
sections, % of opposite hemisphere x2) 
0-100%
lower is better 
24h 
Campolo 
2013(40)  
Lesion volume, mm3 Lesion volume calculated from 2mm sections Lower is better 24h 
Kelso 2011(67) 
Cortical tissue spared, 
mm3 
Percentage of total cortical tissue volume 
0-100 
Higher is better 
12 days 
Lin 2016(68)  Lesion volume, mm3 
Quantitative digital analysis of lesion (0.5mm 
sections) 
Lower is better 8h 
Sarrafzadeh  
2000(71) 
 
Contusion volume, mm3 
Quantitative digital analysis of lesion (0.4mm 
sections) 
Lower is better 24h 
Cerebral oedema     
Dehghan Brain water content, % Brain water content increases as cerebral 0-100 72h
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2013(63)  oedema increases: % water content of whole 
brain calculated by wet weight/dry weight 
method (WW/DW) 
Lower is better 
Lin 2016(68)  8h 
Wu 2016(30) 24h 
Ding 2014(64)  
% ipsilateral hemisphere, WW/DW 
24h 
Ding 2015(65) 24h 
Kabadi 2010(66) 48h 
Sarrafzadeh  
2000(71)  
24h 
Sarrafzadeh  
2000(71) 
Hemispheric swelling, % 
% of contralateral hemisphere; 
[(WWL - WWR)/WWR] X 100 
24h 
Neurological status 
Beni 2004 (62) 
Neurological Severity 
Score (NSS) change 
Change in NSS: Ten Behavioural and motor 
tasks: 1 point awarded for each failed task 
0 - 10 
lower = less 
deterioration 
Change from 
baseline at 1, 4 
and 7 days; 
Ding 2014(64)  
NSS 
NSS total score 
0-10 
Lower is better 
1, 24* and 72h 
Ding 2015(65) Change in NSS 
0-10
Higher is better 
1*, 3 and 7 days 
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Wu 2016(30)  Modified NSS 
Modified NSS  
with motor, sensory, reflex, and balance tests 
0-18 
Lower is better  
24h 
Dehghan 
2013(63)  
Vetnary Coma Score (VCS) 
Neurological status based on motor (1-8),  
visual (1-4), and respiratory responses (1-3) 
3 -15 
Higher is better  
Baseline, 1, 24, 
48 and 72h 
Cognitive performance 
Kelso 2011(67) 
Morris Water Maze 
(MWM) (s) 
MWM Escape latency: time to reach platform 
(max 60s) x 5 trials i) Data acquisition test over 
5 days and ii) retention 3 days later (distance – 
partially reported) 
Maximum 60s 
Lower is better 
i) Day 5-9 
ii) Day 12 
Lin 2016(68) MWM (s) 
Escape latency(s): i) Hidden platform ii) visible 
platform  
Maximum 100s 
Lower is better 
i) Day 11-15  
ii) Day 16 
Ozdemir 
2005(70) 
MWM (s) 
i) Escape latency (s) and 
ii) Time in correct quadrant (s) 
Maximum 60s 
1. Lower is better 
2. Higher is better 
i) Days 1 to 4 
ii) Day 5 
Yamakawa 
2017(72) 
 
Behavioural test battery:
Beam walking (BW); 
Open field (OF); 
Elevated Plus Maze(EPM); 
Novel Context Mismatch 
BW: The beam walking task measures acute 
balance, coordination, and motor disturbances 
(s); 
OF: a measure of locomotion and exploratory 
behavior; 
BW: lower is better
OF: higher is better 
EPM: higher is 
better 
NCM: higher is 
BW day 1; 
OF day 2;  
EPM day 3,  
NCM day 7-10  
FS day 13 
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(NCM); and Force Swim 
(FS) 
EPM: a behavioural test for anxiety; 
NCM: a measure of short-term working 
memory; 
FS: a measure of depressive-like behavior 
better 
FS: lower is better 
Motor function and coordination 
Campolo 
2013(40) 
Rotarod test (s)
 
Time on Rotarod (average of 3 trials) 
0 – 60
Higher is better 
1 and 6h; 
Lin 2016(68) 
Balance beam (s) 
 
Time on beam Higher is better Day 1 to 5 
Mesenge 
1998(69) 
Grip score (s) 
Length of time remains on a string (mainly 
motor function) 
Maximum 0-30  
Higher is better 
24h 
Other outcomes 
Dehghan 
2013(63) 
ICP (mmHg); 
 
Intracranial Pressure measured over 3 days 
(baseline, 1, 24, 48 and 72h) 
Lower is better 72h* 
Bayir 2008(61) 
i) MRI pathology change; 
 
Pathologies categorized: parenchymal or extra 
cerebral hemorrhage, contusion, ventricular 
effacement; 36h  
MRI at 3 hours post-injury, intervention given, 
MRI repeated at 36 hours 
Lower amounts of 
change is more 
favorable i.e. less 
cerebral oedema 
36h 
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ii) Brain protrusion 
through craniotomy 
Maximal extrusion point of brain tissue outside 
craniotomy site 
Lower is better 36 
Kemp 2004(73) 
Sleep diary; 
SCOLP  
AMIPB  
HAD 
Tests for change in memory and information 
processing speeds: i) Neuropsychological Speed 
and Capacity of Language-Processing Test 
(SCOLP); ii) Information processing test from 
Adult Memory and Processing Battery (AMIPB); 
Mood assessment: 
Hospital Anxiety and Depression Scale (HAD) 
0-100 
i) and ii) higher is 
better 
iii) lower is better 
End of each 
treatment arm 
Kuczynski 
2013(46) 
> 50% headache frequency Reduction in headache frequency Dichotomous 
2 months post 
treatment 
* reported 
Neurological Severity Score (NSS)  
Vetnary Coma Score (VCS) 
Morris Water Maze (MWM)  
Beam walking (BW) 
Open field (OF) 
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Elevated Plus Maze (EPM) 
Novel Context Mismatch (NCM) 
Force Swim (FS) 
Intracranial Pressure (ICP) 
Speed and Capacity of Language-Processing Test (SCOLP) 
Information processing test from Adult Memory and Processing Battery (AMIPB) 
Hospital Anxiety and Depression Scale (HAD) 
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Table 4: Methodology quality assessment of included studies using SYRCLE risk of bias tool(58) 
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p
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Ates 2006 2 1 2 2 3 2 3 1 1 17 Y N N 
Bayir 2008 3 1 2 2 3 1 1 1 1 16 N Y N 
Beni 2004 3 1 2 2 2 1 3 1 1 16 N N N 
Campolo 2013 2 1 2 2 2 1 3 1 1 15 Y N N
Dehghan 2013 2 1 2 2 2 1 2 1 1 14 Y N N
Ding 2014 3 1 2 2 1 2 1 1 2 15 N Y N 
Ding 2015 3 1 2 2 1 2 1 3 2 17 N Y N 
Kabadi 2010 3 1 2 2 2 1 3 1 1 16 N N N 
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Kelso 2011 2 1 2 2 2 1 3 1 2 16 Y N N 
Lin 2016 2 1 2 2 2 2 3 1 2 17 Y N N 
Mesenge 1998 2 1 2 2 2 1 1 1 1 13 Y Y N
Ozdemir 2005 3 1 2 1 2 3 3 1 1 17 N N N 
Sarrafzadeh 2000 2 1 2 2 2 1 1 1 1 13 Y N N 
Wu 2016 2 1 2 2 2 1 1 1 1 13 Y Y N 
Yamakawa 2017 1 3 2 1 2 1 3 1 1 15 Y N N 
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Table 5: Table demonstrating mean, standard deviation, effect sizes and 95% confidence intervals for individual pre-clinical study results 
Study  Melatonin Control  
 
 
n mean SD n mean SD p-value 
for mean 
diff (2-
tailed T-
test) 
Bias 
corrected 
effect size 
(Hedges) 
95% CI 
Contusion/lesion size 
Ates(60) 
% 
12 11.7 1.2 12 16.9 1.8 <0.001 -3.274 -2.0 -4.5 
Beni(74) 7 6.2 1.0 7 11.1 1.0 <0.001 -4.454 -2.5 -6.4 
Campolo(40) 
mm3 
10 37.0 4.7 10 56.0 3.2 <0.001 -4.517 -2.9 -6.2 
Kelso(67) 4 84.0 8.0 4 86.0 10.0 0.765 -0.192 1.2 -1.6 
Lin(68) 5 8.0 1.0 5 11.2 0.8 0.001 -3.190 -1.3 -5.1
Sarrafzadeh(71) 
(night) 
8 30.5 12.8 7 41.8 13.9 0.126 -0.796 0.3 -1.8 
Sarrafzadeh(71) (day) 8 35.6 6.8 8 41.8 16.0 0.334 -0.473 0.5 -1.5
Cerebral Oedema  
Dehghan(63) MEL Brain water 7 73.1 0.8 4 75.7 0.4 <0.001 -3.468 -1.6 -5.4 
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5mg/kg content, % 
Dehghan(63) MEL 
20mg/kg 
7 72.9 0.7 3 75.7 0.5 <0.001 -3.879 -1.7 -6.1 
Wu(30) 12 79.8 0.3 12 80.9 0.4 <0.001 -3.004 -1.8 -4.2 
Lin (68) 5 78.4 1.3 5 81.8 1.6 0.006 -2.105 -0.6 -3.7 
Ding 2014 (64)  6 80.2 1.7 6 81.9 1.6 0.104 -0.953 0.2 -2.1
Ding2015  (65)  5 80.4 0.9 5 81.9 0.9 0.029 -1.521 -0.1 -2.9 
Kabadi (75) MEL 
100mg/kg 
8 79.5 0.8 5 80.5 0.8 0.060 -1.110 0.1 -2.3 
Kabadi (75) MEL 
200mg/kg 
8 79.1 0.3 4 80.5 0.6 <0.001 -3.087 -1.4 -4.8 
Sarrafzadeh(71) 7 80.5 0.4 7 80.7 1.1 0.696 -0.199 0.9 -1.2
Sarrafzadeh(71) 
Hemispheric 
swelling, % 
7.9 7 3.4 9.2 7 4.5 0.55 -0.300 0.75 -1.36 
Neurological status
Beni  (74) MEL 
1mg/kg 
NSS 10 4.7 1.0 8 6.5 0.9 0.001 -1.889 -0.8 -3.0 
Beni  (74) MEL 
5mg/kg 
 23 4.5 2.2 8 6.5 0.9 0.019 -0.989 -0.1 -1.8 
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Beni  (74) MEL 
10mg/kg  
8 4.9 2.9 7 6.5 0.8 0.184 -0.684 0.4 -1.7 
Ding (64) NSS 10 2.9 2.5 10 4.9 1.9 0.060 -0.858 0.1 -1.8 
Ding (65) NSS change NSS^ 5 3.2 1.3 5 1.6 1.1 0.075 -1.170 0.2 -2.5 
Wu(30) NSS mNSS 5 7.5 0.4 5 9.5 0.6 <0.001 -3.541 -1.6 5.5 
Dehghan(63) MEL 
5mg/kg  
VSS^ 
7 13.1 0.8 3 11.5 0.9 0.021 1.787 0.2 3.4 
Dehghan(63) MEL 
20mg/kg dose  
7 14.2 0.8 4 11.5 1.0 0.001 2.850 1.1 4.6 
Cognitive function 
Memory and new learning 
Kelso(67) 
MWM 
4 48.4 21.2 4 45.3 34.8 0.884 -0.093 1.3 -1.5 
Lin(68) 10 58.4 16.4 10 80.5 20.6 0.016 -1.137 -0.2 -2.1 
Ozdemir 2005(70) 
5mg/kg 
7 38.8 1.4 4 44.9 3.4 0.002 -2.454 -0.9 -4.1 
Ozdemir 2005(70) 
20mg/kg 
7 40.2 1.6 3 44.9 3.4 0.015 -1.935 -0.3 -3.5 
Yamakawa 2017(72) NCM^ 5 33.7 8.7 5 25 8.7 0.153 0.903 2.2 1.0 
Exploratory behaviour 
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Yamakawa 2017(72) OF^ 5 6132 724 5 4887 724 0.026 1.552 0.1 3.0 
Anxiety 
Yamakawa 2017(72) EPM^ 5 38.9 9.2 5 31.2 6.5 0.163 0.876 -0.4 2.2
Depression 
Yamakawa 2017(72) FS 5 33.8 12.2 5 24.5 7.1 0.179 0.841 0.5 -2.1 
Motor function 
Yamakawa 2017(72) BW 6 5 4.2 6.9 5 5.8 0.786 -0.160 -1.1 1.4 
Campolo(40) MR^ 30.25 10 18.2 25 10 10.27 0.437 0.340 -0.5 1.2 
Lin(68) BB^ 48 10 6.5 25.9 10 6.5 <0.001 3.256 1.9 4.6
Mesenge 
(69) 
Ia 
Grip^ 
18.9 14 10.9 7 8 7.9 0.014 1.150 0.2 2.1 
Ib 17.9 15 11.6 7 8 0.9 0.016 1.108 0.2 2.0 
 IIa 22.8 15 10.1 13.3 5 8.7 0.077 0.928 -0.1 2.0 
 
IIb 15.8 15 12.4 13.3 4 7.8 0.709 0.204 -0.9 1.3 
IIc 10.5 15 13.3 -13.3 4 0.8 0.685 0.221 -0.9 1.3 
IIIa 23.3 15 8.9 14.9 5 8.5 0.081 0.913 -0.1 2.0
IIIb 19.5 15 10.8 14.9 5 8.5 0.400 0.426 -0.6 1.4
IIIc 12.9 15 11.6 -14.9 5 8.5 0.729 0.174 -0.8 1.2 
Intracranial pressure 
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Dehghan(63) MEL 
5mg 
ICP 
12.1 7 1.1 21.9 3 0.7 <0.001 -8.717 
4.7 12.8 
Dehghan(63) MEL 
20mg 10.9 7 1.1 21.9 4 1 <0.001 -9.415 
5.3 13.5 
Bayir (61) 
Brain 
protrusion 
2 6 0.8 3.4 6 1.7 0.098 -0.972 -0.2 2.2 
 
^Higher score = more favourable outcome 
Neurological Severity Score (NSS)  
Morris Water Maze (MWM)  
Novel Context Mismatch (NCM) 
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Figure 1: PRISMA diagram of included and excluded studies 
 
  
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 O
f Q
ue
en
sla
nd
 fr
om
 w
ww
.lie
be
rtp
ub
.co
m 
at 
07
/15
/18
. F
or 
pe
rso
na
l u
se 
on
ly.
 
Page 47 of 50 
 
 
 
47 
Jo
ur
na
l o
f N
eu
ro
tr
au
m
a 
M
el
at
on
in
 a
s a
 tr
ea
tm
en
t a
fte
r T
ra
um
at
ic 
Br
ai
n 
In
ju
ry
: A
 sy
st
em
at
ic 
re
vi
ew
 a
nd
 m
et
a-
an
al
ys
is 
of
 th
e 
pr
e-
cli
ni
ca
l a
nd
 cl
in
ica
l l
ite
ra
tu
re
&
#1
3;
  (
DO
I: 
10
.1
08
9/
ne
u.
20
18
.5
75
2)
 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
 
Figure 2: Assessment of bias in 15 animal studies evaluating the efficacy of Melatonin to 
improve TBI outcome using the SYRCLE risk of bias tool 
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Figure 3: A Forrest Plot demonstrating the effect of Melatonin in comparison to control 
(vehicle) on Pathological Outcome measures in pre-clinical studies of Traumatic Brain 
Injury 
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Figure 4: Forrest Plot demonstrating the effect of Melatonin in comparison to control 
(vehicle) on Behavioural Outcome in pre-clinical studies of Traumatic Brain Injury 
 
 
  
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 O
f Q
ue
en
sla
nd
 fr
om
 w
ww
.lie
be
rtp
ub
.co
m 
at 
07
/15
/18
. F
or 
pe
rso
na
l u
se 
on
ly.
 
Page 50 of 50 
 
 
 
50 
Jo
ur
na
l o
f N
eu
ro
tr
au
m
a 
M
el
at
on
in
 a
s a
 tr
ea
tm
en
t a
fte
r T
ra
um
at
ic 
Br
ai
n 
In
ju
ry
: A
 sy
st
em
at
ic 
re
vi
ew
 a
nd
 m
et
a-
an
al
ys
is 
of
 th
e 
pr
e-
cli
ni
ca
l a
nd
 cl
in
ica
l l
ite
ra
tu
re
&
#1
3;
  (
DO
I: 
10
.1
08
9/
ne
u.
20
18
.5
75
2)
 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
 
Figure 5: Subgroup Meta-analysis: efficacy of intervention versus control (vehicle) in pre-
clinical studies examining single versus multiple dose and early (within 30 minutes) versus 
late treatment (≥1 hour) [Random effects assumed; 95% confidence intervals, CI; Effect of 
heterogeneity, I2; 200mg/kg (1, 12), 5mg/kg (2, 10, 11, 13, 19, 21),  20mg /kg (3, 5, 14, 15), 
100mg/kg (4, 16), 1mg/kg (6),  Nighttime administration (7,17), 10mg/kg (8, 20), Daytime 
administration (9,18) 
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